Drugs Containing Excipient (Inactive Ingredient) C12-15 ALKYL LACTATE

Branded drugs containing C12-15 ALKYL LACTATE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch Health US LLC	JUBLIA	efinaconazole	0187-5400	C12-15 ALKYL LACTATE

Generic drugs containing C12-15 ALKYL LACTATE excipient

Company	Ingredient	NDC	Excipient
Bausch Health US LLC	efinaconazole	0187-5400	C12-15 ALKYL LACTATE

C12-15 Alkyl Lactate Market Dynamics, Pharmaceutical Excipient Status, and Financial Outlook

Last updated: July 31, 2026

C12-15 alkyl lactate is a specialty ester used primarily as an emollient, solvent, spreading agent, and sensory modifier in cosmetics and personal-care products. Its pharmaceutical-excipient market is smaller and less transparent. Public data do not identify a standalone global market size, revenue series, Orange Book listing, or drug-product exclusivity position for C12-15 alkyl lactate.

The commercial outlook is tied to personal-care formulations, specialty solvent demand, bio-based chemistry, and supplier qualification rather than prescription-drug volume. Pharmaceutical adoption is possible in topical, dermatological, and semi-solid products, but each use requires product-specific safety, quality, impurity, and regulatory documentation.

What is C12-15 alkyl lactate?

C12-15 alkyl lactate is a mixture of lactate esters formed from lactic acid and C12-C15 fatty alcohols. The material is generally supplied as a clear, low-viscosity liquid with emollient and solvent properties.

Attribute	Description
Chemical class	Long-chain alkyl esters of lactic acid
Typical composition	Mixture of C12, C13, C14, and C15 alkyl lactates
Primary functions	Emollient, solvent, spreading agent, skin-feel modifier
Main commercial markets	Cosmetics, skin care, sun care, hair care, topical formulations
Pharmaceutical role	Potential excipient for topical and dermatological products
Regulatory identity	Product-specific material identity; not a single defined molecular compound
Public financial disclosure	No major supplier separately reports revenue for this ingredient

The mixed-chain composition differentiates C12-15 alkyl lactate from single compounds such as ethyl lactate, butyl lactate, or lauryl lactate. That composition can affect viscosity, solvency, sensory profile, oxidation stability, and batch-release specifications.

Is C12-15 alkyl lactate an FDA-approved pharmaceutical excipient?

C12-15 alkyl lactate should not be described as an independently FDA-approved pharmaceutical excipient. The FDA generally does not approve excipients through a standalone approval pathway. Instead, excipients gain regulatory acceptance through use in approved drug products, inclusion in FDA databases, or review under a product-specific regulatory submission.

The FDA Inactive Ingredient Database is the main public reference for inactive ingredients used in approved drug products. Inclusion depends on the precise ingredient name, route, dosage form, and maximum potency associated with listed products [1]. A supplier's cosmetic or technical-grade product is not automatically interchangeable with a material used in an approved pharmaceutical formulation.

For a sponsor evaluating C12-15 alkyl lactate, the regulatory file would normally include:

• Exact chemical description and composition range
• Manufacturing process and process controls
• Residual solvents and elemental impurity data
• Assay and identity methods
• Peroxide and degradation specifications
• Microbiological controls where relevant
• Toxicology and local-tolerance data
• Extractables and leachables assessment
• Stability data
• Supplier change-control commitments
• GMP and quality-system documentation

The European Medicines Agency similarly evaluates excipients in the context of medicinal products rather than granting broad, product-independent approval [2].

What are the main uses of C12-15 alkyl lactate?

C12-15 alkyl lactate is most established in topical and cosmetic formulations. Its commercial value comes from formulation performance rather than pharmacological activity.

Topical pharmaceutical applications

Potential pharmaceutical applications include:

• Creams and lotions
• Dermatological emulsions
• Sunscreen and photoprotection products
• Ointment and balm systems
• Transdermal or dermal delivery vehicles
• Medicated cosmetics
• Cleansing products for sensitive skin
• Lipid-rich formulations requiring improved spreadability

The ingredient can reduce greasiness, improve glide, and help disperse oil-soluble ingredients. In topical medicines, those characteristics may support patient acceptability and application uniformity.

C12-15 alkyl lactate is less likely to be selected for oral, injectable, ophthalmic, or inhalation products because those routes impose more demanding requirements for systemic exposure, particulate control, sterility, toxicity, and impurity characterization.

How large is the C12-15 alkyl lactate market?

No authoritative public source reports a standalone market size for C12-15 alkyl lactate. Market research firms typically aggregate the ingredient into broader categories such as cosmetic emollients, specialty esters, personal-care ingredients, or lactic-acid derivatives.

A practical market segmentation is:

Segment	Relative commercial importance	Main demand driver
Skin care and facial care	High	Lightweight sensory profile and emolliency
Sun care	High	Spreading, solubilization, and skin feel
Color cosmetics	Medium	Slip and pigment formulation performance
Hair care	Medium	Conditioning and formulation aesthetics
Pharmaceutical topical products	Low to medium	Excipient qualification and product-specific adoption
Oral or parenteral pharmaceuticals	Low	Limited public evidence of broad use
Industrial applications	Low to medium	Specialty solvent and formulation use

The largest near-term revenue pool is likely personal care, not prescription pharmaceuticals. A supplier's financial exposure therefore depends more on customer retention, formulation wins, and premium positioning than on drug exclusivity.

Which companies supply C12-15 alkyl lactate?

The market is supplied through specialty-chemical manufacturers, cosmetic-ingredient producers, and regional distributors. Product naming varies by supplier, and some companies market the material under trade names rather than the INCI designation.

Known commercial channels include:

• Specialty ester manufacturers
• Producers of lactic-acid derivatives
• Personal-care ingredient suppliers
• Contract manufacturers serving cosmetics and topical pharmaceuticals
• Regional distributors with formulation-support services

Supplier selection typically depends on more than price. Buyers assess:

• Chain-length distribution
• Acid value and ester value
• Color and odor
• Residual alcohol and solvent profile
• Oxidative stability
• Batch-to-batch consistency
• Regulatory support
• Geographic supply redundancy
• Packaging and storage conditions
• Change-notification practices

Public company filings rarely isolate C12-15 alkyl lactate revenue. Companies generally report the product within broader personal-care, specialty ingredients, or performance materials segments.

What drives demand for C12-15 alkyl lactate?

Demand is supported by four commercial factors.

Growth in lightweight skin-care formulations

Consumers and formulators continue to favor products that spread rapidly and leave lower tack and greasiness. Long-chain lactate esters can provide a lighter sensory profile than some conventional mineral, vegetable, or heavy ester oils.

Preference for renewable-carbon chemistry

Lactic acid can be produced through fermentation, creating a potential bio-based positioning. The renewable content of a finished C12-15 alkyl lactate product depends on the source of the lactic acid, the fatty alcohol, and the supplier's manufacturing route. Bio-based claims require documented feedstock and mass-balance substantiation.

Demand for alternatives to volatile silicone materials

Formulators seek non-silicone or silicone-reduced options in some skin-care and sun-care products. C12-15 alkyl lactate may compete with volatile silicones, hydrocarbons, triglycerides, and other specialty esters on sensory performance and regulatory positioning.

Topical drug-delivery development

Topical pharmaceutical companies increasingly optimize vehicle design for penetration, retention, patient adherence, and cosmetic acceptability. This creates opportunities for specialty esters, but adoption is slow because the excipient becomes part of the product's safety and performance package.

How does C12-15 alkyl lactate compare with competing excipients?

Material class	Relative advantage	Main limitation
C12-15 alkyl lactate	Emolliency, spreadability, specialty sensory profile	Limited public pharmaceutical-use history
Ethylhexyl palmitate	Strong emolliency and broad cosmetic use	Heavier sensory profile in some systems
Caprylic/capric triglyceride	Established oil-phase material and broad availability	Can provide a less dry skin feel
Isopropyl myristate	Good spreading and penetration characteristics	Potential irritation and formulation sensitivity
Diethyl sebacate	Solvent and penetration-enhancing utility	Different sensory and regulatory profile
Dimethicone	Slip, barrier, and water-resistance properties	Silicone-positioning constraints
Mineral oil	Low cost and established pharmaceutical history	Less favorable sensory and marketing profile
Ethyl lactate	Renewable solvent profile and low molecular weight	Greater volatility and different solvency behavior

C12-15 alkyl lactate is most competitive where sensory attributes, low tack, and formulation differentiation justify a premium over commodity oils.

What patent protection covers C12-15 alkyl lactate?

C12-15 alkyl lactate has limited apparent patent leverage as a standalone chemical. The basic ester class is chemically conventional, and broad composition-of-matter exclusivity is unlikely to provide a durable commercial barrier.

Potentially relevant rights may instead cover:

• Specific cosmetic or pharmaceutical formulations
• Sunscreen compositions
• Delivery systems using lactate esters
• Defined ratios of emollients and solvents
• Manufacturing or purification processes
• Low-odor or low-color grades
• Bio-based production routes
• Combinations with active pharmaceutical ingredients

A patent search should distinguish between claims directed specifically to C12-15 alkyl lactate and claims that merely list it among hundreds of optional excipients. The latter generally provides weaker practical protection.

IP category	Likely relevance
Standalone composition patent	Low
Formulation patent	Medium to high in specific products
Method-of-use patent	Medium, especially for topical delivery
Manufacturing-process patent	Medium where impurity control or renewable feedstock is distinctive
Supplier trade secret	Medium to high for process economics and quality
Trademark protection	Relevant to commercial differentiation, not exclusivity over the molecule

No Orange Book patent position should be attributed to C12-15 alkyl lactate itself. The Orange Book lists patents associated with approved drug products, not independent excipient ownership [3].

When does C12-15 alkyl lactate lose exclusivity?

C12-15 alkyl lactate does not have a single product-level patent expiration date comparable to an active pharmaceutical ingredient. Any relevant exclusivity would attach to a particular formulation, manufacturing method, delivery system, or branded product.

Generic or competitor entry therefore does not depend on a single patent expiry. Entry risk is shaped by:

• Ability to source equivalent-quality material
• Pharmaceutical-grade documentation
• Formulation performance
• Drug-product regulatory requirements
• Supplier qualification timelines
• Manufacturing scale
• Customer switching costs
• Any formulation or delivery patents held by the drug-product sponsor

A topical drug manufacturer may face low molecule-level barriers but high execution barriers if the incumbent has validated a proprietary excipient specification and secured regulatory approval for a complex formulation.

Are there Paragraph IV challenges involving C12-15 alkyl lactate?

Paragraph IV litigation applies to patents listed for approved drug products under the abbreviated new drug application pathway. It does not apply to C12-15 alkyl lactate as an ingredient sold into the excipient market.

A Paragraph IV dispute could arise indirectly if:

1. A branded topical drug contains C12-15 alkyl lactate.
2. The drug sponsor lists formulation or method-of-use patents in the Orange Book.
3. A generic applicant challenges those patents.
4. The dispute concerns the finished drug product, not ownership of the excipient itself.

No standalone Paragraph IV market exists for C12-15 alkyl lactate.

What is the biosimilar risk for C12-15 alkyl lactate?

Biosimilar risk is not directly relevant. C12-15 alkyl lactate is a small-molecule excipient and is not a biologic drug. It does not face biosimilar competition, reference-product exclusivity, or biologics patent dance procedures under the Biologics Price Competition and Innovation Act.

Competition instead comes from alternative excipients, substitute suppliers, and reformulated drug products.

What financial trajectory is likely for C12-15 alkyl lactate?

The financial trajectory is likely to show moderate volume growth with price pressure in standard grades and higher margins in qualified, documented, or sustainability-positioned grades.

Period	Expected commercial pattern
Near term	Demand supported by skin care and sun care; raw-material and freight volatility remain relevant
Medium term	Growth from silicone-reduction, sensory optimization, and bio-based formulations
Pharmaceutical expansion	Gradual because qualification and regulatory review extend development cycles
Margin outlook	Commodity grades face competition; documented specialty grades retain stronger pricing
Downside risks	Substitution, weak discretionary cosmetics demand, feedstock inflation, and supplier consolidation

Revenue quality depends on the percentage of sales tied to approved or validated formulations. Cosmetic sales can scale faster but are more exposed to brand cycles, retailer inventory, and consumer spending. Pharmaceutical sales tend to be stickier after qualification but require longer customer-development periods.

The strongest economic position is likely held by suppliers that combine manufacturing capacity with formulation support, regulatory files, global distribution, and consistent quality. A producer selling only undifferentiated material is more exposed to price competition.

What manufacturing and IP barriers affect market entry?

Manufacturing C12-15 alkyl lactate is not inherently an extreme technical barrier. Commercial barriers arise from process control and customer qualification.

Important manufacturing variables include:

• Fatty-alcohol feedstock quality
• Esterification conversion
• Catalyst selection
• Water removal
• Residual acid reduction
• Color and odor control
• Unreacted alcohol removal
• Thermal stability
• Packaging compatibility

Pharmaceutical customers may require tighter specifications than cosmetic buyers. A supplier may need separate grades, validated cleaning procedures, audit readiness, and extensive change-control systems.

The most defensible barriers are operational rather than molecule-level patent rights. These include reliable supply, documented impurity control, regulatory support, and successful incorporation into approved or late-stage drug products.

What generic launch scenarios exist for products containing C12-15 alkyl lactate?

Three launch scenarios are common.

Formulation-equivalent generic

The generic sponsor uses the same or functionally equivalent excipient and seeks to demonstrate pharmaceutical equivalence and bioequivalence, where applicable. This is the lowest formulation-risk route if the ingredient is readily qualified.

Design-around formulation

The sponsor replaces C12-15 alkyl lactate with another emollient or solvent. This can avoid formulation patents but may alter spreadability, drug release, skin permeation, preservative performance, or patient acceptability.

505(b)(2) or hybrid development

A sponsor uses a known active ingredient with a new topical vehicle, route, strength, or delivery system. In this case, C12-15 alkyl lactate may be part of the differentiation strategy, while formulation patents and clinical bridging requirements determine commercial protection.

Key Takeaways

• C12-15 alkyl lactate is primarily a cosmetic and personal-care specialty ester, not a standalone pharmaceutical product.
• Public sources do not provide a reliable ingredient-specific global market size or revenue history.
• Pharmaceutical opportunity is concentrated in topical, dermatological, and semi-solid formulations.
• FDA status depends on product-specific use and precise material identity; supplier-grade claims do not equal FDA approval.
• The ingredient has limited apparent molecule-level patent protection.
• Formulation, method-of-use, manufacturing-process, and quality-system rights are more relevant than composition patents.
• Paragraph IV and biosimilar risks apply only indirectly through finished drug products.
• Financial upside is strongest for suppliers offering qualified grades, regulatory documentation, formulation support, and dependable global supply.
• Main competitive threats are substitute emollients, price competition, feedstock volatility, and customer reformulation.

FAQs

Is C12-15 alkyl lactate the same as lactic acid?

No. Lactic acid is an alpha-hydroxy carboxylic acid. C12-15 alkyl lactate is a mixture of esterified products formed from lactic acid and longer-chain fatty alcohols.

Can C12-15 alkyl lactate be used in a pharmaceutical cream?

It can be evaluated for use in a pharmaceutical cream, but acceptance depends on formulation performance, toxicology, manufacturing quality, and regulatory documentation for the specific product.

Is C12-15 alkyl lactate a natural ingredient?

The answer depends on feedstock and production claims. The lactic-acid portion may be fermentation-derived, while the fatty-alcohol portion may be petrochemical, plant-derived, or mass-balanced. “Natural” status requires jurisdiction-specific substantiation.

Does C12-15 alkyl lactate improve drug penetration through skin?

It may influence drug partitioning, spreadability, and skin permeation, but the effect depends on the active ingredient, vehicle composition, concentration, and skin model. It cannot be assigned a universal penetration-enhancing effect.

What is the main investment risk in C12-15 alkyl lactate?

The main risk is limited differentiation. If a supplier lacks proprietary quality specifications, regulatory support, or customer-embedded formulations, buyers may substitute competing esters or switch suppliers based on price.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

2. European Medicines Agency. (2017). Guideline on the quality requirements for medicinal products containing chemical entities. https://www.ema.europa.eu/

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. International Pharmaceutical Excipients Council. (2020). Good manufacturing practices guide for pharmaceutical excipients. IPEC Federation. https://www.ipec-federation.org/

5. European Chemicals Agency. (n.d.). Information on chemicals and chemical substances. https://echa.europa.eu/